Business Context and Reporting Period
Alumis Inc. (ALMS) filed a Current Report on Form 8-K dated May 21, 2025, announcing the completion of its acquisition of ACELYRIN, Inc. Under the terms of the Merger Agreement, ACELYRIN merged with Arrow Merger Sub, Inc., a wholly-owned subsidiary of Alumis, and continues as a wholly-owned subsidiary of Alumis.
Key Financial Metrics and Transaction Terms
This filing details the structural terms of the merger rather than operational financial performance metrics (revenue, profit, cash flow) for the period. Key transaction values include:
- Exchange Ratio: 0.4814 shares of Alumis Common Stock for each share of ACELYRIN common stock.
- Stock Options: Options with an exercise price of $18.00 or less were converted to Alumis options; options with an exercise price above $18.00 were cancelled without consideration.
- RSUs and PSUs: Unvested Restricted Stock Units (RSUs) were converted based on the exchange ratio. Performance Stock Units (PSUs) were deemed met at 100% of target and converted to RSUs.
- Financial Statements: The filing explicitly states that financial statements of the acquired business and pro forma financial information are not included in this report and will be filed within 71 days.
Material Changes
The primary material change is the corporate structure resulting from the merger:
- ACELYRIN is now a wholly-owned subsidiary of Alumis.
- ACELYRIN shareholders received Alumis stock or cash in lieu of fractional shares.
- Alumis equity holders now own a combined entity with ACELYRIN's assets and liabilities.
Corporate Governance and Other Events
Board of Directors Changes:
- The number of authorized directors increased from seven to eight.
- Lynn Tetrault was appointed to the Board as an independent director effective at the closing of the Merger.
- Henry Gosebruch, who was expected to join the Board, will not do so due to his recent appointment as CEO of Galapagos.
- Ms. Tetrault did not receive an initial option grant but will receive compensation consistent with other non-employee directors.
Regulatory Status: Alumis remains classified as an emerging growth company.
Investor Verification Checklist
- Verify the exact number of Alumis shares issued to ACELYRIN shareholders to assess dilution impact.
- Review the upcoming 8-K amendment (due within 71 days) for ACELYRIN's historical financial statements and pro forma combined financial data.
- Confirm the valuation of cancelled ACELYRIN options (those with exercise prices >$18.00) to understand potential employee retention risks.
- Monitor the integration plan for ACELYRIN's operations into Alumis's existing portfolio.